Characteristics of 35 HBV reactivated cases
| No. | Diagnosis | Sex | Age (years) | Disease duration (months) | HBV DNA titre (log copies/mL) | NAA | Clinical course | HBsAb (mIU/ml) | HBcAb (S/CO) | Interval (months) | Medication |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RA | F | 81 | 16 | 2.6 | − | – | 222.6 | 0.5 | 10 | MTX |
| 2 | RA | M | 76 | 95 | 2.3 | + | Worse | 2.16 | 12 | 36 | PSL |
| 3 | RA | M | 86 | 303 | 7.1 | + | Stable | 25.5 | 10.3 | 30 | ABC |
| 4 | RA | F | 80 | 133 | 2.5 | + | Stable | 73.8 | 0.5 | 131 | MTX |
| 5 | RA | F | 60 | 85 | 2.3 | − | Worse | 124.7 | 1.16 | 5 | TAC |
| 6 | RA | F | 81 | 63 | 9.1 | + | Worse | 3.1 | 10.2 | 74 | PSL |
| 7 | RA | F | 70 | 6 | 3.5 | + | Worse | 28.6 | 9.01 | 138 | PSL, MTX |
| 8 | RA | M | 51 | 135 | <2.1 | − | Stable | 0.5 | 8.54 | 86 | TCZ, MTX |
| 9 | RA | F | 71 | 220 | <2.1 | − | Stable | 4.1 | 37.7 | 101 | IFX, MTX |
| 10 | RA | F | 80 | 64 | <2.1 | − | Stable | 1000 | 95.6 | 52 | MTX |
| 11 | RA | M | 79 | 73 | <2.1 | − | Stable | 11.8 | 19.1 | 73 | MTX |
| 12 | RA | M | 70 | 10 | <2.1 | − | Stable | 113.5 | 19.3 | 14 | PSL, TAC |
| 13 | RA | F | 70 | 59 | <2.1 | − | Better | 851 | 2.2 | 38 | ADA, MTX |
| 14 | RA | F | 73 | 409 | <2.1 | − | Better | 13.5 | 7.12 | 27 | ABC, MTX |
| 15 | RA | F | 77 | 64 | <2.1 | − | Better | 9.5 | 5 | 50 | GLM, MTX |
| 16 | RA | F | 76 | 141 | <2.1 | − | Better | 12.63 | 157 | MTX | |
| 17 | RA | M | 65 | 205 | <2.1 | − | Better | 50.2 | 27.9 | 148 | ETA, PSL |
| 18 | RA | F | 72 | 201 | <2.1 | − | Better | 147 | 0.5 | 3 | GLM, PSL, MTX |
| 19 | RA | F | 83 | 6 | <2.1 | − | – | 45 | 10.15 | 14 | ETA |
| 20 | RA | F | 76 | 11 | <2.1 | − | – | 10.8 | 1.23 | 19 | MZB |
| 21 | RA | F | 85 | 23 | <2.1 | − | – | 47.1 | 6.04 | 32 | PSL, MTX |
| 22 | RA | F | 65 | 112 | <2.1 | + | Stable | 5.7 | 8.96 | 90 | MTX |
| 23 | RA | F | 75 | 505 | 2.3 | − | – | 0.4 | 98.5 | 83 | MZB |
| 24 | RA | F | 72 | 39 | <2.1 | − | – | 24.9 | 29.9 | 73 | IFX, MTX |
| 25 | RA | F | 67 | 193 | <2.1 | − | – | 0 | 5.13 | 38 | ABC, MTX |
| 26 | RA | M | 75 | 35 | <2.1 | − | – | 0 | 9.14 | 66 | MTX |
| 27 | RA | F | 81 | 434 | <2.1 | − | – | 1.9 | 8.62 | 56 | MZB |
| 28 | RA | M | 76 | 65 | <2.1 | − | – | 54.2 | 8.79 | 100 | PSL |
| 29 | RA | F | 84 | 157 | <2.1 | − | – | 32.8 | 7.36 | 182 | PSL |
| 30 | RA | F | 82 | 614 | <2.1 | − | – | 155.3 | 2.25 | 39 | PSL |
| 31 | RA | F | 66 | 171 | <2.1 | − | – | 1000 | 5.71 | 87 | MTX |
| 32 | RA | F | 76 | 97 | <2.1 | − | – | 1.4 | 88 | 12 | GLM, PSL |
| 33 | PM | F | 68 | 235 | 2.7 | − | Stable | 3.5 | 8.09 | 87 | PSL |
| 34 | SLE | F | 63 | 84 | 2.3 | + | Worse | 8.78 | 6.54 | 96 | PSL |
| 35 | PMR | M | 82 | 54 | <2.1 | − | Stable | 0.4 | 12.1 | 70 | PSL |
Titres of HBsAb and HBcAb were collected at registration. ‘Age’, ‘Disease duration’, ‘Medication’ and ‘Interval’ between the beginning of immunosuppressive drugs and reactivation were at the point of reactivation. Administration of ‘NAA’ and ‘Clinical course’ was checked at the last observation. HBV DNA titre was the highest value during the observation period. In the column of ‘clinical course’, ‘worse’ means increase of HBV DNA and/or start of NAA, ‘stable’ and ‘better’ reveal ‘unchanged’ and ‘decreased’ HBV DNA levels without using NAA, respectively. The negative ranges of HBsAb and HBcAb are <10.0 mIU/mL and <1.0 S/CO, respectively.
ABC, abatacept; ADA, adalimumab; ETA, etanercept; F, female; GLM, golimumab; HBcAb, hepatitis B virus core antibody; HBsAb, hepatitis B virus surface antibody; HBV, hepatitis B virus; IFX, infliximab; M, male; MTX, methotrexate; MZB, mizoribine; NAA, nucleic acid analogue; PM, polymyositis; PMR, polymyalgia rheumatica; PSL, prednisolone; RA, rheumatoid arthritis; S/CO, sample/cut-off; SLE, systemic lupus erythematosus; TAC, tacrolimus; TCZ, tocilizumab.